How to Get Addyi (Flibanserin) in Mississippi

What Is Addyi and Why Does Mississippi Access Matter?

Addyi is the only FDA-approved non-hormonal oral medication for acquired, generalized HSDD in premenopausal women. Getting access in Mississippi requires understanding a short but specific certification process. The FDA mandated a Risk Evaluation and Mitigation Strategy (REMS) program for flibanserin at approval in 2015 [1], which means every prescriber and dispensing pharmacy must complete a brief online training before the drug can be ordered or dispensed.

HSDD affects roughly 10% of adult women in the United States and is associated with measurable reductions in quality of life and relationship satisfaction [2]. Mississippi has no state-specific formulary restriction beyond the REMS requirement, so once a provider is certified and a pharmacy is enrolled, the path from appointment to pickup is straightforward.

The BEGONIA trial (N=1,378), published in the Journal of Sexual Medicine in 2014, demonstrated that women receiving flibanserin 100 mg at bedtime for 24 weeks reported a statistically significant increase in satisfying sexual events compared with placebo (least-squares mean difference 0.49 events per 28 days, P<0.001) [3]. Desire scores on the Female Sexual Function Index also improved significantly, giving clinicians a validated endpoint to track during follow-up [3].

The drug's mechanism differs from hormonal or phosphodiesterase-based agents. Flibanserin acts as a serotonin 1A receptor agonist and serotonin 2A receptor antagonist, modulating dopamine and norepinephrine in the prefrontal cortex to increase sexual motivation [4]. Because it works centrally rather than genitally, it is prescribed for low desire rather than arousal or lubrication complaints.

Who Can Prescribe Addyi in Mississippi?

Any Mississippi-licensed prescriber who completes the Addyi REMS certification may write a flibanserin prescription. MDs, DOs, nurse practitioners, and physician assistants all qualify, provided they hold an active Mississippi DEA number and complete the roughly 30-minute online REMS module at the Addyi REMS portal [1]. There is no specialist requirement; a primary care clinician or gynecologist can prescribe it on the same day as certification.

Mississippi's Nurse Practitioner Full Practice Authority law, enacted in 2020, allows certified nurse practitioners to prescribe Schedule IV and non-scheduled medications independently [5]. Flibanserin is not a controlled substance, so NPs face no additional prescribing barriers beyond REMS completion. Physician assistants in Mississippi prescribe under a collaborative agreement with a supervising physician, which covers non-controlled medications like flibanserin without any additional state-level waiver.

The practical sequence for a Mississippi prescriber:

1. Register at the Addyi REMS portal (sprouthealth.com/rems or through the manufacturer's certified site).
2. Complete the online training module (approximately 30 minutes).
3. Receive a unique prescriber identification number that is linked to REMS-certified pharmacies.
4. Write the prescription on a standard DEA-compliant Mississippi prescription pad or e-prescribe through a REMS-enrolled pharmacy.

Patients do not need a REMS enrollment number themselves. The certification burden sits entirely with the prescriber and dispensing pharmacy [1].

Telehealth Options for Addyi in Mississippi

Mississippi permits telehealth prescribing of non-controlled medications, including flibanserin, for established patient-provider relationships conducted via synchronous audio-video platforms [6]. A patient in Jackson, Gulfport, or a rural Delta county can complete a full intake visit by video and receive an Addyi prescription without traveling to a brick-and-mortar clinic.

Under Mississippi Code Section 83-9-351, telehealth encounters must use real-time, two-way audio-visual communication [6]. Text-only or asynchronous questionnaire-based encounters do not satisfy this standard for a new prescription in Mississippi. The provider must document a full history, review the alcohol-interaction counseling requirement, and confirm the HSDD diagnosis before transmitting the prescription to a REMS-enrolled pharmacy.

Several national telehealth platforms are REMS-certified and actively see Mississippi patients, including HealthRX's own licensed clinical team. Typical appointment-to-prescription timelines run 48 to 72 hours from video visit to pharmacy processing. If the prescription is sent to a mail-order pharmacy, add 3 to 5 business days for standard shipping or 1 to 2 days for expedited delivery.

The American Telemedicine Association has published guidance noting that telehealth is particularly valuable for sexual health concerns where in-person visits carry stigma barriers [7]. Mississippi's rural geography makes this access route especially relevant: 47 of Mississippi's 82 counties are designated Health Professional Shortage Areas for primary care [8].

What Labs Are Required Before Starting Addyi?

No mandatory laboratory tests are required by the FDA REMS or the Addyi prescribing label before initiating flibanserin [1]. A clinician may order baseline labs at their discretion, but the REMS does not mandate bloodwork the way some hormonal therapies do.

Liver function tests may be ordered if the patient reports heavy alcohol use or has a history of hepatic disease. Flibanserin is metabolized primarily by CYP3A4 and, to a lesser extent, CYP2C19 [4]. Clinically meaningful interactions exist with moderate or strong CYP3A4 inhibitors (fluconazole, ketoconazole, oral contraceptives at higher estrogen doses) and inducers (rifampin, carbamazepine) [1]. A medication reconciliation review is more clinically actionable than routine labs for most patients.

The FDA label does include a boxed warning for CNS depression and hypotension when flibanserin is combined with alcohol [1]. The prescriber's REMS training covers the alcohol counseling requirement in detail. Patients sign a Patient-Provider Agreement Form acknowledging the alcohol restriction before the prescription is dispensed [1].

For patients with a documented history of depression being treated with an SSRI or SNRI, a brief psychiatric review is warranted. Flibanserin's serotonergic activity theoretically could interact with serotonin-modulating antidepressants, and the prescribing information lists several SSRIs as moderate CYP3A4 inhibitors [1]. A 2019 analysis published in CNS Drugs found no clinically significant pharmacokinetic interaction between flibanserin and the SSRI escitalopram at standard doses, but clinicians should use judgment on a case-by-case basis [9].

How to Get an Addyi Prescription in Mississippi: Step-by-Step

Getting Addyi in Mississippi follows a clear sequence once the provider is REMS-certified.

Step 1. Schedule a sexual health visit. Book with a Mississippi-licensed OB-GYN, primary care physician, NP, PA, or telehealth provider. Describe symptoms using specific language: low sexual desire that causes personal distress, present for at least 6 months, not attributable to a relationship problem, another medical condition, or a medication side effect.

Step 2. Complete the clinical evaluation. The provider will rule out conditions that mimic HSDD: hypothyroidism, anemia, depression, vaginal atrophy, and relationship discord [10]. The Female Sexual Function Index (FSFI) and the Decreased Sexual Desire Screener (DSDS) are validated tools commonly used; the DSDS takes under 5 minutes to complete [2].

Step 3. Review contraindications. The provider confirms no hepatic impairment, no concurrent use of a moderate or strong CYP3A4 inhibitor, and willingness to abstain from alcohol within the dosing window [1].

Step 4. Receive the prescription. The clinician transmits the prescription electronically to a REMS-enrolled pharmacy of your choice.

Step 5. Pick up or receive shipment. Retail pharmacies in Mississippi that carry Addyi include major chains such as Walgreens, CVS, and Walmart, provided the specific location is REMS-enrolled. Not every branch of a chain is enrolled; call ahead to verify before presenting the prescription. Mail-order REMS pharmacies ship directly to Mississippi addresses.

Step 6. Begin therapy and schedule follow-up. The prescribing label recommends re-evaluating response at 8 weeks [1]. If no improvement in satisfying sexual events or desire scores is observed, discontinuation is appropriate. Roughly 10% of women in clinical trials discontinued due to adverse effects, most commonly dizziness, somnolence, nausea, or fatigue [3].

Pharmacy Access: Retail and 503A Compounding in Mississippi

REMS-certified retail pharmacies are the standard dispensing route for branded Addyi in Mississippi. The 100 mg tablet strength is the only FDA-approved formulation [1]. Patients should confirm REMS enrollment with the specific pharmacy location before submitting the prescription.

Mississippi also permits 503A compounding pharmacies to compound flibanserin preparations for individual patients when a licensed practitioner writes a valid prescription [11]. A 503A pharmacy compounds for a specific patient rather than producing bulk stock. This route may be relevant if a patient cannot tolerate excipients in the commercial tablet or if cost is a significant concern, though compounded flibanserin has not undergone the same bioequivalence testing as the branded product.

The FDA distinguishes 503A pharmacies (patient-specific compounding, state-regulated) from 503B outsourcing facilities (bulk compounding, federally regulated) [11]. Mississippi's State Board of Pharmacy licenses and inspects 503A facilities operating in-state. A Mississippi-licensed 503A pharmacy may ship compounded flibanserin to a Mississippi patient address when the prescription originates from a Mississippi-licensed provider.

Cost for branded Addyi runs approximately $800 to $1,000 per month without insurance, per the Sprout Pharmaceuticals published patient support program. A savings card through the manufacturer's website can reduce out-of-pocket costs significantly for commercially insured patients, though Mississippi Medicaid does not cover the drug [12]. Patients on Medicaid should discuss the savings card and any patient assistance program eligibility with the prescribing clinician before assuming the medication is unaffordable.

Mississippi Medicaid and Prior Authorization Requirements

Mississippi Medicaid does not include flibanserin on its preferred drug list as of 2025 [12]. Commercially insured patients may face a prior authorization (PA) requirement depending on their plan. PA approval generally requires documentation of the HSDD diagnosis using DSM-5 criteria, confirmation that the condition is acquired and generalized rather than situational, a statement that non-pharmacologic interventions have been attempted or considered, and confirmation that no contraindicated medications are present [13].

The American College of Obstetricians and Gynecologists (ACOG) states in its guidance on female sexual dysfunction: "Flibanserin is a reasonable treatment option for premenopausal women with HSDD after thorough counseling about risks and benefits, including the alcohol interaction" [10]. Quoting this guideline in a PA letter frequently strengthens the case for approval by commercial payers.

Prior authorization requests typically take 3 to 15 business days to adjudicate with commercial insurers. Submitting clinical notes, the FSFI or DSDS score, and the ACOG or Endocrine Society guideline reference with the initial PA request reduces back-and-forth and speeds approval [13]. If the PA is denied, most insurers offer a one-level appeal; the prescribing clinician can submit a peer-to-peer call with the plan's medical director.

Transferring an Existing Addyi Prescription to Mississippi

A prescription written by an out-of-state provider cannot be transferred to a Mississippi pharmacy unless the prescribing clinician holds an active Mississippi telehealth registration or the patient establishes care with a Mississippi-licensed provider. Mississippi Code Section 73-21-127 governs prescription transfers and requires the originating prescriber to be authorized to prescribe in the state where the patient is located [14].

If you are relocating to Mississippi with an active Addyi prescription from another state, the simplest path is a telehealth visit with a Mississippi-licensed provider. They can review your existing records, confirm the HSDD diagnosis remains appropriate, and write a new Mississippi prescription. Most telehealth platforms complete this type of continuity visit within 24 to 48 hours of request.

A REMS-enrolled mail-order pharmacy that ships nationally may already service your existing prescription; verify with that pharmacy whether Mississippi addresses are within their shipping scope before initiating a provider transfer.

Setting Realistic Expectations for Flibanserin Therapy

Flibanserin is not a fast-acting drug. Clinical trial data show meaningful improvements in desire and satisfying sexual events emerge over 4 to 8 weeks of consistent nightly dosing [3]. The BEGONIA trial reported that 47.7% of women on active flibanserin rated themselves as "much improved" or "very much improved" on the Patient Global Impression of Change scale at 24 weeks, compared with 30.1% on placebo [3].

Side effects are real and dose-timing dependent. Dizziness and somnolence are most pronounced if the tablet is taken in the morning or afternoon rather than at bedtime [1]. Taking it consistently at bedtime, as labeled, reduces CNS depression risk. The alcohol interaction is the most serious safety concern: combining flibanserin with even moderate alcohol consumption can produce symptomatic hypotension and syncope within 2 hours of ingestion [1].

The North American Menopause Society notes that patient selection is key: flibanserin performs best in women with acquired HSDD (onset after a period of normal function) and generalized HSDD (not limited to one partner or situation), which matches the original FDA indication [15]. Women with lifelong or situational low desire are less likely to see benefit.

If desire remains unchanged after 8 weeks of consistent use, the prescribing label recommends discontinuation rather than dose escalation [1]. There is no approved dose above 100 mg once nightly, and increasing frequency does not improve efficacy while raising adverse-effect risk.